Blue Horseshoe Stocks: Options Roundup

Dicks Sporting Goods, Inc. DKS – Recap

We cast a wide net with respect to the DKS options we included in yesterday’s premarket report, marking the Weekly $35-40 Calls for observation on the heels of the company’s earnings release.

While there were gains on the table for all ten of the contracts in our specified range, we won’t list all of them out, but rather just provide the bottom and the top of the range, and let our readers fill in the blanks.

The $35 Calls ran from 1.50-3.99 for an intraday move of 166%  The $40′s traded up from .10-.45, representing an upswing of 350%  Agiain, increasing, commensurate gains were available throughout our designated range of contract sets.


HP, Inc. HPQ – Recap

We also formulated an idea for the HPQ options chain in yesterday’s report, the HPQ Weekly $21-22 Calls, and were presented with some big single session moves there as well, including a five and a six-bagger!

This was another post-earnings idea, which is generally when we like to strike, at a time when price action and volatility are increased to significant levels. It provided for the following chances for profit:

$21 Calls – Range: .40-1.21 – Max Gain: 214%
$21.50 Calls – Range: .11-.76 – Max Gain: 590%
$22 Calls – Range: .05-.35 – Max Gain: 600%


Fresh Options Ideas – We’ll finish up this morning’s options-heavy report by including a couple of new sets of ideas:

Burlington Stores, Inc. BURL Weekly $141-144 Calls
General Motors Co. GM Weekly $40-42 Calls


Extended Watchlist:
AIPT, BCLI, NGL, NAK, TGA, SESN, VKTX

Incoming search terms:

  • \*@bcli org\

Blue Horseshoe Stocks: IDXG Update & More

Interpace Diagnostics Group, Inc. IDXG

We tracked IDXG last week over a couple of stellar sessions that led to a swing of more than 400%, cautioning that a dip-and-rip could be in the cards after seeing such a volatile move to the upside.

That’s exactly what we’ve seen in the past couple of days, as IDXG came down to find support at the .865 level, and in the ensuing three sessions it’s been steadily registering higher highs and higher lows, getting back to 1.25 yesterday (+45%).

We’ll continue to follow this story, which kicked off with the revelation that Aetna would cover Interpace’s ThyraMir™ test for its 46 million insured members. (>>View PR)


Experience Art & Design, Inc. EXAD

We had EXAD tagged in yesterday’s premarket report and this subpenny play produced a moderate run to kick off the session, even as the larger markets were struggling with the Fed rate hike announcement.

From an early low of .0023, the stock took just the first hour of trading to find its way up to a high of .0038, for a 65% pop. IDXG hung around that level until around lunchtime, and it did come back down to its daily low toward the close, so we’ll be looking for the possibility of a rebound.


Catalyst Biosciences, Inc. CBIO

We’re also interested in following the activity of CBIO today, which is gapping up in the premarket to the tune of more than 100% and looks like it could be lining up to have a big day. We’ll want to make sure it holds above its 50DMA (.80) on any pullbacks, but if it can breach past its 200DMA of 1.31, things could get very interesting.

News broke yesterday via an 8-K filing that CBIO had entered into a definitive agreement with Wyeth LLC, (wholly-owned subsidiary of Pfizer Inc.) to transfer exclusive rights to research, develop, manufacture and commercialize Factor VIIa variants, CB 813a and CB 813d, as well as transferring the investigational NDA to CBIO as well. (>>View Filing)



Fresh Options Idea: 
Transocean, Inc. RIG $15 and $14.50 Puts


Extended Watchlist:
VCEL, NWBO, BCLI, BPMX, DLOV, PPMT

Blue Horseshoe Stocks: VLTC Recap & More

Voltari Corp. VLTC

A unique opportunity presented itself when billionaire activist investor Carl Icahn disclosed his increased position in VLTC (52% ownership) on April 1st. We tagged the stock in our premarket report that morning as it was gapping up, and have become more and more pleased with that decision as time goes on.

After witnessing a low of 2.18 the following day, it has been mostly northward movement as the stock has slowly but surely made its way to impressive new highs. We’ve been tracking it all along the way, with routine followup mentions on the 8th, 10th, 16th, and again in yesterday’s report.

During yesterday’s session VLTC made a nice move from a low of 8.75 to a new 52-week high of 10.41 at the close. It marked a healthy intraday run of 19%, and represents an overall increase of 377% from our observed low on April 2nd.

Anyone trading in this play has certainly thought of taking profits by this point, and reasonably so. That being said, with a high-profile investor like Icahn involved, we’ll have to be sure we don’t let VLTC slip off of our radars as we go forward.

When we finally do see a consolidation off of this historic run, we’ll immediately transition into bottom-watch mode and lay in wait for a subsequent rebound.


Pazoo, Inc. PZOO

We also want to give a quick update on PZOO, which as our readers are aware, we’ve been tracking pretty heavily in recent weeks. Like VLTC, it was also April 1st that we re-introduced this one into the mix. We’ve witnessed many intraday swings since then, that have offered multiple opportunities for successful trades.

Yesterday, the stock made its way from a daily low .0093 and spiked 18% to a new high of .011. That means that from the low of .0049 we observed on April 6th, PZOO had increased by a total of 124% It also closed at .0105; we’d like to see the stock work toward building a base of support at that key penny-level, however on any potential pullbacks we’ll want to see it hold support at or above the channel between the current 50DMA of .0074 and .008.

As we mentioned yesterday, we’re still rather “high” on marijuana-related stocks and PZOO remains one of our favorite ones, in its unique niche of medical cannabis testing/analysis.


Extended Watchlist:
LRCX, MYL, BIOC, BCLI, IBIO, LRE, TWDL, WSTI

Blue Horseshoe Stocks: BCLI Recap & More

BrainStorm Cell Therapeutics, Inc. BCLI

2015 is upon us and our first order of business is to address one of the stocks we tagged in Wednesday’s premarket report. BCLI had a strong session, as it pushed its way up from an early low of 4.02 to an aftyernoon high of 4.94; a solid +23% performance.

The strong session was apparently aided by the pre-emptive PR the company released which served as a reminder that results from Phase 2a trials of its ALS (Lou Gehrig’s Disease) treatment would be released on Monday. This morning the stock is gapping up wildly as anticipation grows, having already hit a premarket high of 7.28, which represents a total increase of 81% over the low we observed on New Year’s Eve.

Monday’s data release, which is expected to be positive, should most likely produce one of two effects. Either the results will beat expectations and facilitate another strong move, or they will fail to meet the mark and cause a pullback. In case of the latter, there may be rebound opportunities waiting just around the corner.



RedHill BioPharma Ltd. RDHL & NephroGenex, Inc. NRX

We also had this pair of standouts appear in Wednesday’s report, with each stock making a similar move. Both started the day with significant spikes in PPS, followed by a tapering off into the close.

RDHL made a sensational jump beginning almost immediately at the open running from 12.52 on up to 17.85 before its pullback, an intraday spike equaling 42.5%. Coincidentally, the stock ended the session having traded 42.5X its 3-month average volume.

NRX
saw an initial low of 12.96, followed by a healthy 39% run to a high of 17.98. This play would offer one more opportunity in the form of an intraday swing as it came down and rebounded off of the 12.60-mark before returning to 15.15, an added 20% move, bringing the day’s cumulative total of possible gains to 59% .


Extended Watchlist:
CUR, ARWR, CLF, MSTX, RAD

Blue Horseshoe Stocks: Final Report of 2014

Good Morning Traders! Here it is- the final report of 2014! We had an amazing year, with huge gainers popping out of the woodwork left, right, and center! We want to take this opportunity to thank all of our readers for being a part of our community, wish you all a Happy New Year while reminding everyone that the best is yet to come… Each year our resolution remains the same: To make the upcoming year our best one ever! We’ve succeeded time and time again, and have no reason to believe that 2015 will be any different so be sure to stay with us! Cheers!


NeuroDerm Ltd. NDRM
NDRM exceeded all expectations yesterday after we caught it on an early morning news scan; it spent the entire day in full-on breakout mode setting records in both price and volume, trading almost 27X the norm over the six week period since the stock’s IPO.

Positive response to yesterday’s early morning press statement hurtled NDRM from an early low of 8.16 all the way up to 19.07 just prior to the close, making gains of up to 134% possible.

We’ll still be standing at the ready for an eventual course correction and chance for a dip-and-rip maneuver, but any way you slice it, NDRM is getting marked down as a huge winner. It’s a great way to close out what has, on the whole, been an absolutely stellar year.

NeuroDerm Announces Topline Results of Phase IIa Pharmacokinetic Study of ND0612H and ND0612L, Continuous, Subcutaneously Delivered Levodopa/Carbidopa for the Treatment of Parkinson’s Disease (Tue 7:00AM EST)


Precious Metals on Watch: Gold, Silver

GDX and SLV have each been maintaining higher highs and higher lows since reaching a bottom in November. As we head into the New Year, we’re going to devote a good amount of focus to gold and silver, and tracking these indices and their options chains is going to be a good way to do that.

In particular, we’re going to be monitoring a few specific sets of contracts for each play:

  SLV – March $15-15.50 Calls

GDX – March $17.50-$18 Calls

As you can see from the side-by-side chart we drew up below, GDX and SLV are looking similarly ripe. We’ve got SLV breaking the 50-Line on the RSI, and GDX following closely behind in that regard, we’re seeing testing of the 50DMA’s on both charts, and each of the MACD’s are giving the indication of bullish crosses.


Side Note:
We’re also going to radar HMCP, a sub-penny momentum play that has had an interesting past few sessions.


Extended Watchlist:
NRX, RDHL, MIG, CYTK, NEON, BCLI, CVEO